GO8128: MRFF 2026 BioMedTech Incubator

The 2026 BioMedTech Grant Opportunity is part of the Medical Research Future Fund under the Medical Research Commercialisation Initiative.

This opportunity looks to fund suitable organisations to identify, select and support Australian SMEs undertaking early-stage medical research and medical innovation projects that have commercial potential.

The intended outcome of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by increasing the number of SMEs developing novel biomarkers, diagnostics, therapeutics, assistive devices and/or digital technologies that have progressed through the early stages of research and development to the point where they are 'de-risked' and attractive to private investment for commercialisation.

Applicants may propose to support development of innovations in their area/s of strength (i.e. applicants are not required to propose a program that covers the breadth of the biomedtech sector).

Joint applications are permitted with a lead organisation that meets the eligibility criteria.

All members of the research team must be listed as Chief Investigators (CIs); a Chief Investigator A (CIA) must be nominated to lead the project.

Applications may include up to 15 CIs; if more than 15 are included the application will be ineligible.

A person must not be named as a CI on more than one application to this grant opportunity.

Applications must include evidence from the board (or CEO or equivalent) that the project is supported and that the applicant can complete the project and meet costs not covered by grant funding, and letters of support from each project partner where applicable.

You must not commence the project until a grant agreement is executed.

Projects must be completed within 5 years of the project start date, unless an extension is approved by the Program Delegate.